March 27, 2018
Asahi Kasei Pharma and RaQualia Pharma have concluded a licensing agreement for a novel P2X7 receptor antagonist discovered through their research collaboration as a candidate drug for the treatment of neuropathic pain, the companies said on March 26. Under the...read more